Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CADI-05 + Pembrolizumab in LA-HNSCC
NCT07455032Phase 1Recruiting
- Sponsor
- Fox Chase Cancer Center
- Start
- Apr 2026
- Primary completion
- Nov 2027
- Modality
- Prophylactic Vaccines, Microbiome Therapeutics, Therapeutic Vaccines
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of MYCIDAC-C in head and neck squamous cell carcinoma (HNSCC), sponsored by Fox Chase Cancer Center. Primary endpoints: Dose Limiting Toxicities at 13 weeks and Grade 3 and higher Adverse Events at 27 months. Started Apr 2026; status: recruiting.
02
Drugs
MYCIDAC-C
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on NCT07455032.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07455032.